Details for Patent: RE47221
✉ Email this page to a colleague
Which drugs does patent RE47221 protect, and when does it expire?
Patent RE47221 protects RINVOQ LQ and RINVOQ and is included in two NDAs.
This patent has one hundred and twenty-eight patent family members in forty-one countries.
Summary for Patent: RE47221
| Title: | Tricyclic compounds |
| Abstract: | The invention provides compounds of Formula (I) and Formula (II) pharmaceutically acceptable salts, pro-drugs, biologically active metabolites, stereoisomers and isomers thereof wherein the variable are defined herein. The compounds of the invention are useful for treating immunological and oncological conditions. |
| Inventor(s): | Neil Wishart, Kristine E. Frank, Michael Friedman, Dawn M. George, Kent D. Stewart, Grier A. Wallace |
| Assignee: | AbbVie Inc |
| Application Number: | US15/446,102 |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for patent RE47221 |
|
Patent Claim Types: see list of patent claims | Compound; |
Drugs Protected by US Patent RE47221
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Abbvie | RINVOQ LQ | upadacitinib | SOLUTION;ORAL | 218347-001 | Apr 26, 2024 | RX | Yes | Yes | RE47221 | ⤷ Start Trial | Y | ⤷ Start Trial | ||||
| Abbvie | RINVOQ | upadacitinib | TABLET, EXTENDED RELEASE;ORAL | 211675-001 | Aug 16, 2019 | RX | Yes | No | RE47221 | ⤷ Start Trial | Y | ⤷ Start Trial | ||||
| Abbvie | RINVOQ | upadacitinib | TABLET, EXTENDED RELEASE;ORAL | 211675-002 | Jan 14, 2022 | RX | Yes | No | RE47221 | ⤷ Start Trial | Y | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent RE47221
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| European Patent Office | 2506716 | ⤷ Start Trial | CA 2020 00011 | Denmark | ⤷ Start Trial |
| European Patent Office | 2506716 | ⤷ Start Trial | 301035 | Netherlands | ⤷ Start Trial |
| European Patent Office | 2506716 | ⤷ Start Trial | 122020000011 | Germany | ⤷ Start Trial |
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
